


Nicole Fitzgerald, MPA, CPS Governor's Office of Drug Policy





USE

Idaho ranks 5th in the nation for pain reliever misuse




- Idahoans aged 18 to 25 were significantly more likely to report misusing prescription drugs.
- Idahoans were more likely to misuse prescription drugs in every age group compared to the percentage for the United States.

SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2015 and 2016

USE

OVER 1 IN 7 IDAHO HIGH SCHOOL STUDENTS HAVE EVER MISUSED PRESCRIPTION DRUGS.


1 IN 50 HAVE TRIED HEROIN



SAMHSA, Center for Behavioral Health Statistics and Quality, National Survey on Drug Use and Health, 2015 and 2016


Drug-induced Death

FIGURE 1. Age-adjusted mortality rate trend for drug-induced deaths: Idaho residents and the United States¹, 2000-2016.



^{*2016} data for the United States has not been released.


¹Source: CDC Wonder



■ No opioid involvement


Drug(s) not specified

Opioids involved




Source: Idaho Bureau of Vital Records and Health Statistics

Rate of Drug Overdose Deaths reporting Opioid involvement by Public Health District of Residence 2011-2015*



PRESCRIPTIONS


Idaho ranks 17th in the nation in the total number of opioid prescriptions dispensed/100 persons




Centers for Disease Control and Prevention, Prescribing Map, 2016

PRESCRIPTIONS


Variation by county in the total number of opioid prescriptions dispensed/100 persons





Source: Centers for Disease Control & Prevention, 2016

Quarterly rate of people with ≥1 opioid prescription per 1,000 Idaho residents, 2016–2017



9/7/2018

Resources

Opioid Misuse & Overdose Workgroup & Strategic Plan

www.odp.idaho.gov

Idaho's Response to the Opioid Crisis (IROC)

https://healthandwelfare.idaho.gov/ search IROC

To refer anyone to IROC call 1-800-922-3406

Live Better Idaho

https://www.livebetteridaho.org/

2-1-1 Helpline

Call 211

Nicole Fitzgerald, Administrator

Nicole.fitzgerald@odp.Idaho.gov 208-854-3040






Treatment of Opioid Use Disorder

Magni Hamso, MD, MPH Clinical Assistant Professor, University of Washington-Boise Internal Medicine Residency Internal Medicine Physician, TRHS mhamso@trhs.org @MagniMD

Disclosures

TERR

- No financial disclosures.
- Will use generic names when possible.
 - Buprenorphine/naloxone instead of Suboxone.
 - "Bupe" for short.
- Will use PollEverywhere



Answers to this poll are anonymous



W Why did you choose to attend this talk?



How knowledgeable are you about medication assisted treatment?

This is brand new to me!

I've heard a little bit about it

Pretty knowledgeable

Expert

Goals of Talk




- Understand the scope of the opioid overdose epidemic
- Define opioids, opioid use disorder (OUD), addiction
 & recovery
- Identify evidence-based treatments for OUD
- Understand why buprenorphine/naloxone is an effective treatment for OUD

How the Epidemic of Drug Overdose Deaths Ripples Across America



By HAEYOUN PARK and MATTHEW BLOCH JAN. 19, 2016







Deaths from overdoses are reaching levels similar to the


H.I.V. epidemic at its peak.

115 AMERICANS






3 Waves of the Rise in Opioid Overdose Deaths



SOURCE: National Vital Statistics System Mortality File.



CDC's Unique Work In Action: Overdose Deaths are the Tip of the Iceberg



Results from the 2015 National Survey on Drug Use and Heatth: Detailed Tables https://www.samnsa.gov/gata/sites/getauit/files/NSDUH-DetTabs-2015/N

What are Opioids?


- Prescription pain medicines such as hydrocodone (Norco), oxycodone, morphine, fentanyl
- Illegal drugs such as heroin
- Stimulate the opioid receptor in the brain to decrease pain, as side effects make people feel good (euphoria) and slow breathing (overdose risk)















What is Addiction?



- "a primary, chronic disease of brain reward, motivation, memory, and related circuitry...
- ...pathologically pursuing reward and/or relief of withdrawal symptoms by substance use...
- ...Without treatment or engagement in recovery, addiction is progressive and can result in disability and death."






Slide Credit: Dr. John Giftos, Clinical Director SUD Treatment, Correctional Health Services



Natural History of Opioid Dependence




"When you can stop you don't want to, and when you want to stop, you can't."

Luke Davies, Candy. 1998.



Oriminal Justice Exposure Common for Patients with Opioid Use Disorder



In addition to fact that heroin possession/use is illegal, increased tolerance and physical dependence often lead to criminal activity in order to sustain drug use.









Opioid Use Disorder

Clinical term for the chronic disease of addiction



- Diagnostic criteria include:
 - escalating use & loss of control
 - continued use despite negative consequences
 - diminished ability to fulfill societal obligations
 - tolerance to the effects of the drug
 - withdrawal symptoms when the drug is stopped

Who is affected?





Who is affected?




- 70 year-old grandfather, relapsed after 40 years
- 28 year-old homeless insulin-dependent diabetic
- 32 year-old pregnant stay-at-home mom on opioids since last c-section
- 50 year-old using painkillers after work injury
- 44 year-old small business owner



How can we help these individuals? What treatments can we offer?

Treatment





Harm Reduction

- Practical strategies & ideas aimed at reducing negative consequences of drug use
 - Meeting users where they are at
 - Substance use a continuum from severe use to abstinence
 - Complete abstinence not always the goal
 - Empower & give voice to people who use drugs



Harm Reduction

TERRY

- Safe injection technique
- Clean needles
- HIV, Hepatitis C testing
- Hepatitis A & B vaccination
- Naloxone (Narcan) for reversal of opioid

overdose



What is Recovery?




- "a process of *sustained action* that addresses the biological, psychological, social and spiritual disturbances...
- aims to improve the quality of life...
- is the consistent *pursuit* of abstinence"



Treatment























Opioid Agonist Therapy


Methadone

Buprenorphine

Opioid Antagonist

Extendedrelease Naltrexone





Opioid Antagonist Therapy



Opioid Antagonist

Extendedrelease Naltrexone

- Once monthly intramuscular injection
- Blocks intoxicating/reinforcing effects of opioids
- Some interest pre-release
- High relapse rates, limited evidence
- Increased risk of overdose after antagonist wears off



Opioid Agonist Therapy



Opioid Agonist Therapy

Methadone

Buprenorphine

Reduce withdrawal symptoms & cravings

→ prevent relapse → allow brain to heal

↓mortality ↓ HIV/HCV **↓** substance use

↓ criminal activity ↑ retention in treatment

Opioid Agonist Therapy




Opioid Agonist Therapy


Methadone

Buprenorphine









Methadone vs Buprenorphine



Methadone	Buprenorphine		
Full agonist	Partial agonist		
Typical dose 80-120mg/d	Typical dose 16mg/d		
Treatment Program (daily dosing)	Office based (prescription)		
Stigma	Managed like any other chronic illness		
More risky, especially during induction phase	Protected from overdose (ceiling effect, tight bond to receptors)		
Better for patients who need more structure, heavier opioid use	Bound to naloxone to prevent diversion and misuse		





Addiction





- Escalating use over time
- Loss of control; inability to stop
- Use despite negative consequences
- Unable to fulfill societal obligations

Dependence




 Presence of withdrawal symptoms if substance stopped abruptly

Methadone and buprenorphine result in physical dependence but **not** addiction.

Retain in Treatment, Prevent Relapse






Time from randomisation (days)

Retain in Treatment, Prevent Relapse



Figure 2. Treatment Retention and Mean Buprenorphine Dosage for Patients With Prescription Opioid Dependence



Mean buprenorphine dosage, mg/d

Maintenance condition 14.9 15.1 15.2 15.3 15.3 16.0 15.9 16.2 16.2 16.6 16.8 16.2 16.1 15.8 14. Taper condition 15.6 15.4 15.3 14.2 9.7 5.7 3.1 0.6 0.2 0 0 0 0 0

Reduce HIV, HCV



Baseline Characteristic	Incident HCV, No. of Participants	Person-years of Observation	Incidence per 100 Person-years (95% CI) ^a	RR (95% CI)	P Value
Overall	171	680	25.1 (21.6-29.2)	NA	NA
Drug treatment in past 3 mo ^b					
None	138	488	28.2 (23.9-33.4)	1 [Reference]	
Non-OA therapy	15	84	17.9 (10.8-29.6)	0.63 (0.37-1.08)	.09
OA detoxification	11	27	41.1 (22.8-74.2)	1.45 (0.80-2.69)	.23
Maintenance OA therapy ^c	7	81	8.6 (4.1-18.1)	0.31 (0.14-0.65)	.001

70% lower risk of acquiring hepatitis C on methadone or buprenorphine



Reduce Mortality






FIGURE 1—Heroin overdose deaths and opioid agonist treatment: Baltimore, MD, 1995–2009.

Reduce Mortality



- Recent meta-analysis showed reduction in allcause mortality and overdose-related mortality
 - Three times higher mortality rate out of methadone treatment
 - Five times higher <u>overdose</u> mortality rate out of methadone treatment

Buprenorphine Treatment



Day 1: Intake (counselor & MD visit, agreement, urine drug screen, PMP, labs)

Home Induction

Day 4: MD visit

Week 1: MD & counselor visit

Week 2/3/4: MD & counselor visit

Week 6/8: MD & counselor visit





Urine drug screens each visit.

Monthly visits once patient doing well.

Recommend LONG TERM treatment, typically a year or longer;

some need lifelong treatment.

W What are the biggest barriers to care?

Cost

Health Insurance

Stigma

Licensed prescribers

Other

What can employers do?



- Naloxone for reversal of opioid overdose on site and easily accessible
- Information about how to access care
- Support staff struggling with opioid use disorder, as would support employees with other chronic medical conditions
- Ensure coverage of substance use disorders and mental health care





In the unfortunate circumstance where an employee finds that he or she is dependent upon or addicted to opioid painkillers, help needs to be clear and accessible. Employee-sponsored treatment is more effective than treatment encouraged by family or friends. Retaining an employee following successful treatment is good for morale and the company's bottom line.

Employers committed to safe and healthy workplaces have a responsibility to address the opioid epidemic. These employers can do so with strong employee policies, alliances with health benefits and workers' compensation plan providers, education, expanded drug-free workplace testing and access to treatment programs.

The proactive role employers can take: OPIOIDS IN THE WORKPLACE

SAVING JOBS, SAVING LIVES AND REDUCING HUMAN COSTS

Want to learn more?



- https://www.samhsa.gov/medicationassisted-treatment
- https://odp.idaho.gov/opioids-and-overdoses/
- https://www.nsc.org/

Questions?



mhamso@trhs.org